Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mordechai Grupper"'
Publikováno v:
Journal of Clinical Microbiology. 55:3502-3512
The effectiveness of antimicrobial binding resins present in blood culture (BC) bottles in removing meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam is unknown. We assessed the time to detection (TTD) and growth of 2 Pseudomonas aeruginos
Autor:
Brenna L. Hughes, Morgan L. Swank, Lindsay Maggio, David P. Nicolau, Joseph L. Kuti, Mordechai Grupper
Publikováno v:
The Journal of Clinical Pharmacology. 57:712-719
The optimal antibiotic prophylaxis dosing regimen of cefazolin for cesarean delivery (CD) in overweight and obese women is unknown. This study was done to compare the duration that cefazolin concentrations remain above the minimum inhibitory concentr
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
A novel antibiotic combination of the oral cephalosporin ceftibuten (CTB) and the β-lactamase inhibitor clavulanate (CLA) is currently in development for urinary tract infections, including those caused by extended-spectrum-β-lactamase (ESBL)-produ
Publikováno v:
Clinical Microbiology Reviews. 29:759-772
SUMMARY Beta-lactam antibiotics serve as a cornerstone in the management of bacterial infections because of their wide spectrum of activity and low toxicity. Since resistance rates among bacteria are continuously on the rise and the pipeline for new
Autor:
Tanya M. Gottlieb, Neta Petersiel, Dani Kirshner, Liran Shani, Kfir Oved, Meital Paz, Salim Halabi, Michael Drescher, Ami Neuberger, Michal Stein, Gali Kronenfeld, Noa Avni, Eran Eden, Ynon Lishtzinsky, Shirly Yanai, Mordechai Grupper, Michal Paul, Yasmin Maor, Shachaf Shiber
Publikováno v:
Open Forum Infectious Diseases
Background Challenges in determining the etiology of acute exacerbations of chronic obstructive pulmonary disease (COPD) lead to significant overuse of antibiotics. A new host-response assay that integrates the levels of three proteins (TRAIL, IP-10,
Publikováno v:
Journal of pharmacy practice. 30(6)
Objectives: To evaluate the pharmacodynamic exposure of piperacillin/tazobactam across the renal function range using 4.5 or 3.375 g dosing regimens. Methods: A 5000-patient Monte Carlo simulation was conducted to determine the probability of achievi
Publikováno v:
Infectious diseases (London, England). 49(11-12)
Acinetobacter baumannii(ACBN) is a MDR organism causing pneumonia in ventilated patients. High MICs often result in insufficient lung exposures, thus poor outcomes have been observed with parenteral antimicrobials. Amikacin Inhale(AMK-I), is a drug-d
Autor:
David P. Nicolau, Mordechai Grupper
Publikováno v:
Current opinion in infectious diseases. 30(2)
Skin and soft tissue infections (SSTIs) are prevalent in the obese population, with rising trend expected. Although numerous antibiotics are available for the prevention and treatment of SSTIs, their characterization in obese patients is not a regula
Publikováno v:
Annals of Clinical Microbiology and Antimicrobials
Background Amikacin inhale (BAY41-6551), a unique drug—device combination of a specially formulated drug solution and a pulmonary drug delivery system device (AMK-I) is currently under phase III study as an adjunctive therapy to IV antibiotics for
Publikováno v:
European journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology. 36(5)